MedTrace Logo

TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.

NCT05233098 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2025-03-06

Study results available
· View outcomes & findings →

Summary

The TheraSphere Post-Approval Study is a post-market, prospective, single-arm, open-label, observational study to support the use of TheraSphere for the treatment of hepatocellular carcinoma (HCC).

Conditions

Interventions

DEVICE

Technetium-99m macroaggregated albumin (Tc-99m MAA)

Patients who are being evaluated for TheraSphere administration.

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Riad Salem, MD · Northwestern University

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-04
Primary Completion
2023-06-14
Completion
2023-06-14
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05233098 on ClinicalTrials.gov